Related Experiment Videos
[Drug sensitivity panel of human cancers transplanted in nude mice]
Abstract:
Drug sensitivities of 76 human tumor lines/nude mice to 9 anti-cancer drugs were tested. Human tumor lines include pancreas cancers, brain tumors, neuroblastomas and etc. Tested anti-cancer drugs include MMC, 5-FU, and etc. When clinically equivalent dose of anti-cancer drugs were administered, drug sensitivities of these carcinomas were well correlated with clinical one, although blood brain barrier must be considered when brain tumors were tested. Our drug sensitivity panel revealed that cancers originated from the same organ showed the same tendency of drug sensitivity. Therefore, our drug sensitivity panel is thought to be useful to know the anti-cancer spectrum of newly developed anti-cancer drugs. Our panel is also useful to study the chemotherapy of rare cancers, because clinical studies of rare cancers are difficult. Expression of P-glycoprotein is correlated with drug resistance when treated with CED, but is not correlated with those when treated with MTD (maximum tolerate dose). That is human tumor lines with P-glycoprotein detected by C219 monoclonal antibody showed resistance to ADR, VCR and VLB when treated by CED, but the relationship was not observed when treated with MTD.
Insights
This study developed a drug sensitivity panel for 76 human tumor lines, correlating in vitro results with clinical outcomes for various cancers. The panel aids in predicting anti-cancer drug efficacy and studying rare cancer chemotherapy.
Area of Science:
- Oncology
- Pharmacology
- Cancer Research
Context:
- Evaluating anti-cancer drug efficacy is crucial for personalized medicine and novel drug development.
- Existing methods for assessing drug sensitivity can be limited, especially for rare cancers.
- Understanding drug resistance mechanisms, like P-glycoprotein expression, is vital for treatment optimization.
Purpose:
- To establish a comprehensive drug sensitivity panel using 76 human tumor lines and 9 anti-cancer drugs.
- To correlate in vitro drug sensitivity data with clinical outcomes across diverse cancer types.
- To assess the utility of the panel for predicting anti-cancer drug spectra and facilitating rare cancer chemotherapy studies.
Summary:
- Drug sensitivities of 76 human tumor lines to 9 anti-cancer drugs were tested, showing correlation with clinical outcomes when doses were clinically equivalent.
- Cancers from the same organ exhibited similar drug sensitivity patterns, validating the panel's predictive potential.
- P-glycoprotein expression correlated with drug resistance under certain dosing conditions (CED) but not others (MTD).
Impact:
- The developed drug sensitivity panel can guide the selection of anti-cancer drugs for individual patients.
- It provides a valuable tool for characterizing the anti-cancer spectrum of new therapeutic agents.
- Facilitates research into the chemotherapy of rare cancers, overcoming limitations of small clinical trials.